Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc∞ of mesna was approximately 8% of the AUC∞ of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.
|Original language||English (US)|
|Number of pages||5|
|Journal||Cancer Chemotherapy and Pharmacology|
|Publication status||Published - Jun 1 2003|
ASJC Scopus subject areas
- Cancer Research